Rufloxacin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Rufloxacin
Accession Number
DB13772
Type
Small Molecule
Groups
Experimental
Description

Rufloxacin is a quinolone antibiotic. [1]

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Rufloxacin hydrochloride1643374N6L106017-08-7LPQOADBMXVRBNX-UHFFFAOYSA-N
Categories
UNII
Y521XM2900
CAS number
101363-10-4
Weight
Average: 363.407
Monoisotopic: 363.105290352
Chemical Formula
C17H18FN3O3S
InChI Key
NJCJBUHJQLFDSW-UHFFFAOYSA-N
InChI
InChI=1S/C17H18FN3O3S/c1-19-2-4-20(5-3-19)14-12(18)8-10-13-16(14)25-7-6-21(13)9-11(15(10)22)17(23)24/h8-9H,2-7H2,1H3,(H,23,24)
IUPAC Name
7-fluoro-6-(4-methylpiperazin-1-yl)-10-oxo-4-thia-1-azatricyclo[7.3.1.0⁵,¹³]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
SMILES
CN1CCN(CC1)C1=C(F)C=C2C(=O)C(=CN3CCSC1=C23)C(O)=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may increase the neuroexcitatory activities of Rufloxacin.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Rufloxacin.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Rufloxacin.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Rufloxacin.Experimental, Illicit
AcarboseThe therapeutic efficacy of Acarbose can be increased when used in combination with Rufloxacin.Approved, Investigational
AceclofenacAceclofenac may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational
AcemetacinAcemetacin may increase the neuroexcitatory activities of Rufloxacin.Approved, Experimental, Investigational
AcenocoumarolRufloxacin may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Rufloxacin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Rufloxacin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Rufloxacin.Approved, Vet Approved
AdapaleneAdapalene may increase the neuroexcitatory activities of Rufloxacin.Approved
AlbiglutideRufloxacin may increase the hypoglycemic activities of Albiglutide.Approved
AlclofenacAlclofenac may increase the neuroexcitatory activities of Rufloxacin.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Rufloxacin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Rufloxacin.Experimental, Investigational
AlmasilateAlmasilate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlminoprofenAlminoprofen may increase the neuroexcitatory activities of Rufloxacin.Experimental
AlogliptinRufloxacin may increase the hypoglycemic activities of Alogliptin.Approved
AloglutamolAloglutamol can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AluminiumAluminium can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Rufloxacin.Experimental, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Rufloxacin.Approved
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Rufloxacin.Approved
AmiodaroneThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Amiodarone.Approved, Investigational
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Rufloxacin.Approved, Investigational, Withdrawn
AndrographolideAndrographolide may increase the neuroexcitatory activities of Rufloxacin.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Rufloxacin.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Rufloxacin.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Rufloxacin.Investigational
AnisodamineAnisodamine may increase the neuroexcitatory activities of Rufloxacin.Investigational
AntipyrineAntipyrine may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational
ApocyninApocynin may increase the neuroexcitatory activities of Rufloxacin.Investigational
ApremilastApremilast may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Rufloxacin.Investigational
AzapropazoneAzapropazone may increase the neuroexcitatory activities of Rufloxacin.Withdrawn
AzelastineAzelastine may increase the neuroexcitatory activities of Rufloxacin.Approved
BalsalazideBalsalazide may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of tendinopathy can be increased when Beclomethasone dipropionate is combined with Rufloxacin.Approved, Investigational
BendazacBendazac may increase the neuroexcitatory activities of Rufloxacin.Experimental
BenorilateBenorilate may increase the neuroexcitatory activities of Rufloxacin.Experimental
BenoxaprofenBenoxaprofen may increase the neuroexcitatory activities of Rufloxacin.Withdrawn
BenzatropineThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Benzatropine.Approved
BenzydamineBenzydamine may increase the neuroexcitatory activities of Rufloxacin.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Rufloxacin.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Rufloxacin.Approved, Investigational
BevoniumBevonium may increase the neuroexcitatory activities of Rufloxacin.Experimental
Bismuth subcitrate potassiumBismuth Subcitrate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BromfenacBromfenac may increase the neuroexcitatory activities of Rufloxacin.Approved
BrompheniramineThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Brompheniramine.Approved
BucillamineBucillamine may increase the neuroexcitatory activities of Rufloxacin.Investigational
BudesonideThe risk or severity of tendinopathy can be increased when Budesonide is combined with Rufloxacin.Approved
BufexamacBufexamac may increase the neuroexcitatory activities of Rufloxacin.Approved, Experimental
BumadizoneBumadizone may increase the neuroexcitatory activities of Rufloxacin.Experimental
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Rufloxacin.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Rufloxacin.Approved
Calcium AcetateCalcium Acetate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium ChlorideCalcium Chloride can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CitrateCalcium Citrate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium glubionateCalcium glubionate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium GluceptateCalcium Gluceptate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium gluconateCalcium gluconate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Calcium lactateCalcium lactate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
Calcium lactate gluconateCalcium lactate gluconate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium levulinateCalcium levulinate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Calcium pangamateCalcium pangamate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium PhosphateCalcium Phosphate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CanagliflozinRufloxacin may increase the hypoglycemic activities of Canagliflozin.Approved
Carbaspirin calciumCarbaspirin calcium may increase the neuroexcitatory activities of Rufloxacin.Experimental, Investigational
CarprofenCarprofen may increase the neuroexcitatory activities of Rufloxacin.Approved, Vet Approved, Withdrawn
CaseinCasein can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CastanospermineCastanospermine may increase the neuroexcitatory activities of Rufloxacin.Experimental
CelecoxibCelecoxib may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational
CetirizineThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Cetirizine.Approved
ChloroquineChloroquine may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Chlorphenamine.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the neuroexcitatory activities of Rufloxacin.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Rufloxacin.Approved, Investigational
CinnarizineThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Cinnarizine.Approved, Investigational
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Ciprofloxacin.Approved, Investigational
ClemastineThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Clemastine.Approved, Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Rufloxacin.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Rufloxacin.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Rufloxacin.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Rufloxacin.Approved
ClonixinClonixin may increase the neuroexcitatory activities of Rufloxacin.Approved
ClorindioneRufloxacin may increase the anticoagulant activities of Clorindione.Experimental
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Rufloxacin.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Rufloxacin.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Rufloxacin.Approved, Investigational
CurcuminCurcumin may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Rufloxacin.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Rufloxacin.Experimental
DapagliflozinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Rufloxacin.Approved
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Rufloxacin.Approved, Investigational
DelamanidRufloxacin may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Rufloxacin.Approved
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Rufloxacin.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Rufloxacin.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Rufloxacin.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Rufloxacin.Experimental, Vet Approved
DexamethasoneThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Rufloxacin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Rufloxacin.Vet Approved
DexbrompheniramineThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Dexbrompheniramine.Approved
DiclofenacDiclofenac may increase the neuroexcitatory activities of Rufloxacin.Approved, Vet Approved
DicoumarolRufloxacin may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Rufloxacin.Approved
DifenpiramideDifenpiramide may increase the neuroexcitatory activities of Rufloxacin.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Rufloxacin.Approved
DiflunisalDiflunisal may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Rufloxacin.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Rufloxacin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Rufloxacin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Rufloxacin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Rufloxacin.Approved
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Dimenhydrinate.Approved
DiphenadioneRufloxacin may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Rufloxacin.Approved, Investigational
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Rufloxacin.Approved, Investigational
DoxylamineThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Doxylamine.Approved, Vet Approved
DroxicamDroxicam may increase the neuroexcitatory activities of Rufloxacin.Withdrawn
DulaglutideRufloxacin may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuvelisibDuvelisib may increase the neuroexcitatory activities of Rufloxacin.Investigational
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Rufloxacin.Approved
E-6201E-6201 may increase the neuroexcitatory activities of Rufloxacin.Investigational
EmpagliflozinRufloxacin may increase the hypoglycemic activities of Empagliflozin.Approved
EpirizoleEpirizole may increase the neuroexcitatory activities of Rufloxacin.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Rufloxacin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Rufloxacin.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Rufloxacin.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Rufloxacin.Approved
EthenzamideEthenzamide may increase the neuroexcitatory activities of Rufloxacin.Experimental
Ethyl biscoumacetateRufloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational
EtoricoxibEtoricoxib may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational
ExenatideRufloxacin may increase the hypoglycemic activities of Exenatide.Approved, Investigational
ExisulindExisulind may increase the neuroexcitatory activities of Rufloxacin.Investigational
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Rufloxacin.Approved
FelbinacFelbinac may increase the neuroexcitatory activities of Rufloxacin.Experimental
FenbufenFenbufen may increase the neuroexcitatory activities of Rufloxacin.Approved
FenoprofenFenoprofen may increase the neuroexcitatory activities of Rufloxacin.Approved
FentiazacFentiazac may increase the neuroexcitatory activities of Rufloxacin.Experimental
FeprazoneFeprazone may increase the neuroexcitatory activities of Rufloxacin.Experimental
Ferric CarboxymaltoseThe serum concentration of Rufloxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved
Ferric pyrophosphateThe serum concentration of Rufloxacin can be decreased when it is combined with Ferric pyrophosphate.Experimental
Ferulic acidFerulic acid may increase the neuroexcitatory activities of Rufloxacin.Experimental
FloctafenineFloctafenine may increase the neuroexcitatory activities of Rufloxacin.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Fluasterone is combined with Rufloxacin.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Rufloxacin.Approved, Investigational
FluindioneRufloxacin may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Rufloxacin.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Rufloxacin.Approved, Investigational
FlunixinFlunixin may increase the neuroexcitatory activities of Rufloxacin.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the neuroexcitatory activities of Rufloxacin.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Rufloxacin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Rufloxacin.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Rufloxacin.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Rufloxacin.Approved, Investigational
FluoxetineThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Fluoxetine.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Rufloxacin.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Rufloxacin.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Rufloxacin.Approved
FlurbiprofenFlurbiprofen may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Fluticasone is combined with Rufloxacin.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Rufloxacin.Approved
Fluticasone propionateThe risk or severity of tendinopathy can be increased when Fluticasone propionate is combined with Rufloxacin.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Rufloxacin.Approved, Investigational, Withdrawn
GanciclovirThe metabolism of Ganciclovir can be decreased when combined with Rufloxacin.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Rufloxacin.Experimental
GlimepirideThe therapeutic efficacy of Glimepiride can be increased when used in combination with Rufloxacin.Approved
GlipizideThe therapeutic efficacy of Glipizide can be increased when used in combination with Rufloxacin.Approved, Investigational
GlyburideThe therapeutic efficacy of Glyburide can be increased when used in combination with Rufloxacin.Approved
GoserelinThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Goserelin.Approved
GuacetisalGuacetisal may increase the neuroexcitatory activities of Rufloxacin.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Rufloxacin.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Rufloxacin.Investigational
HigenamineHigenamine may increase the neuroexcitatory activities of Rufloxacin.Investigational
HydrocortisoneThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Rufloxacin.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of tendinopathy can be increased when Hydrocortisone acetate is combined with Rufloxacin.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of tendinopathy can be increased when Hydrocortisone butyrate is combined with Rufloxacin.Approved, Vet Approved
HydrotalciteHydrotalcite can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
HydroxyzineThe risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Rufloxacin.Approved
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Rufloxacin.Approved, Investigational
IbuprofenIbuprofen may increase the neuroexcitatory activities of Rufloxacin.Approved
IbuproxamIbuproxam may increase the neuroexcitatory activities of Rufloxacin.Withdrawn
IcatibantIcatibant may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational
Imidazole salicylateImidazole salicylate may increase the neuroexcitatory activities of Rufloxacin.Experimental
IndobufenIndobufen may increase the neuroexcitatory activities of Rufloxacin.Investigational
IndomethacinIndomethacin may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational
IndoprofenIndoprofen may increase the neuroexcitatory activities of Rufloxacin.Withdrawn
Insulin AspartRufloxacin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirRufloxacin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be increased when used in combination with Rufloxacin.Approved
Insulin GlulisineRufloxacin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be increased when used in combination with Rufloxacin.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be increased when used in combination with Rufloxacin.Approved
IronThe serum concentration of Rufloxacin can be decreased when it is combined with Iron.Approved
Iron DextranThe serum concentration of Rufloxacin can be decreased when it is combined with Iron Dextran.Approved, Vet Approved
Iron saccharateThe serum concentration of Rufloxacin can be decreased when it is combined with Iron saccharate.Approved
IsoxicamIsoxicam may increase the neuroexcitatory activities of Rufloxacin.Withdrawn
IsradipineThe risk or severity of QTc prolongation can be increased when Isradipine is combined with Rufloxacin.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Rufloxacin.Investigational
KebuzoneKebuzone may increase the neuroexcitatory activities of Rufloxacin.Experimental
KetoprofenKetoprofen may increase the neuroexcitatory activities of Rufloxacin.Approved, Vet Approved
KetorolacKetorolac may increase the neuroexcitatory activities of Rufloxacin.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Rufloxacin.Experimental
Lanthanum carbonateThe serum concentration of Rufloxacin can be decreased when it is combined with Lanthanum carbonate.Approved
LeflunomideLeflunomide may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational
LeuprolideThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Leuprolide.Approved, Investigational
LiraglutideRufloxacin may increase the hypoglycemic activities of Liraglutide.Approved
LisofyllineLisofylline may increase the neuroexcitatory activities of Rufloxacin.Investigational
LonazolacLonazolac may increase the neuroexcitatory activities of Rufloxacin.Experimental
LoratadineThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Loratadine.Approved, Investigational
LornoxicamLornoxicam may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Rufloxacin.Approved
LoxoprofenLoxoprofen may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational
LumiracoxibLumiracoxib may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium salicylateThe serum concentration of Rufloxacin can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium sulfateMagnesium sulfate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
MasoprocolMasoprocol may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Rufloxacin.Investigational
MecaserminRufloxacin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the neuroexcitatory activities of Rufloxacin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Rufloxacin.Approved
Mefenamic acidMefenamic acid may increase the neuroexcitatory activities of Rufloxacin.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Rufloxacin.Vet Approved
MeloxicamMeloxicam may increase the neuroexcitatory activities of Rufloxacin.Approved, Vet Approved
MepyramineThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Mepyramine.Approved, Vet Approved
MesalazineMesalazine may increase the neuroexcitatory activities of Rufloxacin.Approved
MetamizoleMetamizole may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational, Withdrawn
MetforminThe therapeutic efficacy of Metformin can be increased when used in combination with Rufloxacin.Approved
MethylprednisoloneThe risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Rufloxacin.Approved, Vet Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Rufloxacin.Experimental
MetoclopramideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Rufloxacin.Approved, Investigational
MizoribineMizoribine may increase the neuroexcitatory activities of Rufloxacin.Investigational
MofebutazoneMofebutazone may increase the neuroexcitatory activities of Rufloxacin.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Rufloxacin.Approved, Vet Approved
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Rufloxacin.Approved
NabumetoneNabumetone may increase the neuroexcitatory activities of Rufloxacin.Approved
NafamostatNafamostat may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational
NaftifineNaftifine may increase the neuroexcitatory activities of Rufloxacin.Approved
NaproxenNaproxen may increase the neuroexcitatory activities of Rufloxacin.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Rufloxacin.Investigational
NepafenacNepafenac may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational
NicardipineThe risk or severity of QTc prolongation can be increased when Nicardipine is combined with Rufloxacin.Approved, Investigational
NifenazoneNifenazone may increase the neuroexcitatory activities of Rufloxacin.Experimental
Niflumic AcidNiflumic Acid may increase the neuroexcitatory activities of Rufloxacin.Approved
NimesulideNimesulide may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may increase the neuroexcitatory activities of Rufloxacin.Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Rufloxacin.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Rufloxacin.Investigational
OlopatadineOlopatadine may increase the neuroexcitatory activities of Rufloxacin.Approved
OlsalazineOlsalazine may increase the neuroexcitatory activities of Rufloxacin.Approved
OndansetronThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Ondansetron.Approved
OrgoteinOrgotein may increase the neuroexcitatory activities of Rufloxacin.Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Rufloxacin.Approved
OxaprozinOxaprozin may increase the neuroexcitatory activities of Rufloxacin.Approved
OxyphenbutazoneOxyphenbutazone may increase the neuroexcitatory activities of Rufloxacin.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Rufloxacin.Approved, Vet Approved
PalmidrolPalmidrol may increase the neuroexcitatory activities of Rufloxacin.Experimental, Nutraceutical
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Rufloxacin.Approved
ParecoxibParecoxib may increase the neuroexcitatory activities of Rufloxacin.Approved
ParoxetineThe risk or severity of QTc prolongation can be increased when Paroxetine is combined with Rufloxacin.Approved, Investigational
ParthenolideParthenolide may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational
PeruvosidePeruvoside may decrease the cardiotoxic activities of Rufloxacin.Experimental
PhenindioneRufloxacin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniramineThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Pheniramine.Approved
PhenprocoumonRufloxacin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the neuroexcitatory activities of Rufloxacin.Approved, Vet Approved
PimecrolimusPimecrolimus may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational
PirfenidonePirfenidone may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational
PiroxicamPiroxicam may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational
PirprofenPirprofen may increase the neuroexcitatory activities of Rufloxacin.Experimental
PramlintideRufloxacin may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PranoprofenPranoprofen may increase the neuroexcitatory activities of Rufloxacin.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Rufloxacin.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Rufloxacin.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Rufloxacin.Approved, Investigational
PrednisoloneThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Rufloxacin.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Rufloxacin.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Rufloxacin.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Rufloxacin can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinProglumetacin may increase the neuroexcitatory activities of Rufloxacin.Experimental
PromethazineThe risk or severity of QTc prolongation can be increased when Promethazine is combined with Rufloxacin.Approved, Investigational
PropacetamolPropacetamol may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational
PropafenoneThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Propafenone.Approved
PropyphenazonePropyphenazone may increase the neuroexcitatory activities of Rufloxacin.Experimental
ProquazoneProquazone may increase the neuroexcitatory activities of Rufloxacin.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Rufloxacin.Experimental
PTC299PTC299 may increase the neuroexcitatory activities of Rufloxacin.Investigational
QuetiapineThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Quetiapine.Approved
QuinaprilQuinapril can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ResveratrolResveratrol may increase the neuroexcitatory activities of Rufloxacin.Approved, Experimental, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Rufloxacin.Approved
RofecoxibRofecoxib may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational, Withdrawn
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be increased when used in combination with Rufloxacin.Approved, Investigational
SalbutamolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Rufloxacin.Approved, Vet Approved
SalicylamideSalicylamide may increase the neuroexcitatory activities of Rufloxacin.Approved
Salicylic acidSalicylic acid may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational, Vet Approved
SalmeterolThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Rufloxacin.Approved
SalsalateSalsalate may increase the neuroexcitatory activities of Rufloxacin.Approved
SaxagliptinThe therapeutic efficacy of Saxagliptin can be increased when used in combination with Rufloxacin.Approved
SemapimodSemapimod may increase the neuroexcitatory activities of Rufloxacin.Investigational
SeratrodastSeratrodast may increase the neuroexcitatory activities of Rufloxacin.Approved
SerrapeptaseSerrapeptase may increase the neuroexcitatory activities of Rufloxacin.Investigational
SevelamerSevelamer can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be increased when used in combination with Rufloxacin.Approved, Investigational
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SRT501SRT501 may increase the neuroexcitatory activities of Rufloxacin.Investigational
Strontium ranelateThe serum concentration of Rufloxacin can be decreased when it is combined with Strontium ranelate.Approved, Withdrawn
SucralfateThe serum concentration of Rufloxacin can be decreased when it is combined with Sucralfate.Approved
SulfasalazineSulfasalazine may increase the neuroexcitatory activities of Rufloxacin.Approved
SulfisoxazoleRufloxacin may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational
SunitinibRufloxacin may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenSuprofen may increase the neuroexcitatory activities of Rufloxacin.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the neuroexcitatory activities of Rufloxacin.Experimental
TarenflurbilTarenflurbil may increase the neuroexcitatory activities of Rufloxacin.Investigational
TenidapTenidap may increase the neuroexcitatory activities of Rufloxacin.Experimental
TenoxicamTenoxicam may increase the neuroexcitatory activities of Rufloxacin.Approved
TepoxalinTepoxalin may increase the neuroexcitatory activities of Rufloxacin.Vet Approved
TeriflunomideTeriflunomide may increase the neuroexcitatory activities of Rufloxacin.Approved
TerodilineThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Terodiline.Experimental
TheophyllineThe metabolism of Theophylline can be decreased when combined with Rufloxacin.Approved
Tiaprofenic acidTiaprofenic acid may increase the neuroexcitatory activities of Rufloxacin.Approved
TinoridineTinoridine may increase the neuroexcitatory activities of Rufloxacin.Investigational
TioclomarolRufloxacin may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Rufloxacin.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational
TolmetinTolmetin may increase the neuroexcitatory activities of Rufloxacin.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Rufloxacin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Rufloxacin.Approved, Vet Approved
TribenosideTribenoside may increase the neuroexcitatory activities of Rufloxacin.Experimental
TriptolideTriptolide may increase the neuroexcitatory activities of Rufloxacin.Investigational
Trolamine salicylateTrolamine salicylate may increase the neuroexcitatory activities of Rufloxacin.Approved
TromethamineTromethamine can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Rufloxacin.Approved
ValaciclovirThe metabolism of Valaciclovir can be decreased when combined with Rufloxacin.Approved, Investigational
ValdecoxibValdecoxib may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational, Withdrawn
Valproic AcidThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Valproic Acid.Approved, Investigational
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Rufloxacin.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Rufloxacin.Approved
VenlafaxineThe risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Rufloxacin.Approved
WarfarinRufloxacin may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenZaltoprofen may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational
ZileutonZileuton may increase the neuroexcitatory activities of Rufloxacin.Approved, Investigational, Withdrawn
Zinc acetateZinc acetate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Zinc chlorideZinc chloride can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
Zinc oxideZinc oxide can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ZomepiracZomepirac may increase the neuroexcitatory activities of Rufloxacin.Withdrawn
Food Interactions
Not Available

References

General References
  1. Rafalsky V, Andreeva I, Rjabkova E: Quinolones for uncomplicated acute cystitis in women. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD003597. doi: 10.1002/14651858.CD003597.pub2. [PubMed:16856014]
External Links
Human Metabolome Database
HMDB0042009
KEGG Drug
D02474
KEGG Compound
C11240
ChemSpider
52489
ChEBI
8909
ChEMBL
CHEMBL295619
Wikipedia
Rufloxacin
ATC Codes
J01MA10 — Rufloxacin

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.96 mg/mLALOGPS
logP0.13ALOGPS
logP0.83ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)5.4ChemAxon
pKa (Strongest Basic)6.09ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area64.09 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity97.02 m3·mol-1ChemAxon
Polarizability36.42 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03k9-0169000000-0ec29246738d7398bc4e

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Quinoline carboxylic acids
Direct Parent
Quinoline carboxylic acids
Alternative Parents
Fluoroquinolones / N-arylpiperazines / Haloquinolines / Hydroquinolones / Aminoquinolines and derivatives / Benzothiazines / Hydroquinolines / Pyridinecarboxylic acids / Dialkylarylamines / N-methylpiperazines
show 16 more
Substituents
Quinoline-3-carboxylic acid / Fluoroquinolone / N-arylpiperazine / Aminoquinoline / Haloquinoline / Dihydroquinolone / Benzothiazine / Dihydroquinoline / Pyridine carboxylic acid / Pyridine carboxylic acid or derivatives
show 35 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
quinolines, quinolone antibiotic, fluoroquinolone antibiotic (CHEBI:8909)

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da

Drug created on June 23, 2017 14:48 / Updated on August 15, 2018 14:01